A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

September 14, 2023 updated by: Jiangsu HengRui Medicine Co., Ltd.

A Phase Ib/II Multicenter, Open-Label Clinical Trial of SHR-A1811 Injection in Combination With Pyrotinib or Pertuzumab or Adebrelimab or Paclitaxel for Injection (Albumin Bound) in Breast Cancer

To evaluate the safety, tolerability and efficacy of SHR-A1811 in combination with pyrotinib or pertuzumab or adebrelimab or albumin-bound paclitaxel in patients with breast cancer.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
402

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • China
    • Jiangsu
      • Nanjing, Jiangsu, China, 210029
        • Recruiting
        • Jiangsu Provincial People's Hospital
        • Principal Investigator:
          • Jinhai Tang
        • Principal Investigator:
          • Yongmei Yin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  1. Women aged 18 to 75 (inclusive)
  2. Breast cancer confirmed by histology or cytology.
  3. ECOG score is 0 or 1
  4. An expected survival of ≥ 12 weeks
  5. At least one measurable lesion according to RECIST v1.1 criteria
  6. Have adequate renal and hepatic function
  7. Patients voluntarily joined the study and signed informed consent

Exclusion Criteria:

  1. Have other malignancies within the past 5 years
  2. Active central nervous system metastasis without surgery or radiotherapy
  3. Presence with uncontrollable third space effusion
  4. Have undergone other anti-tumor treatment within 4 weeks before the first dose
  5. Immunosuppressant or systemic hormone therapy was used within 2 weeks prior to the first dose
  6. Any active autoimmune disease or a history of autoimmune disease
  7. A history of immune deficiency
  8. Clinically significant cardiovascular disorders
  9. Clinically significant history of lung disease
  10. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I
  11. Known hereditary or acquired bleeding tendency
  12. Active hepatitis and liver cirrhosis
  13. Presence of other serious physical or mental diseases or laboratory abnormalities

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: SHR-A1811combined Pyrotinib
Drug: SHR-A1811：Pyrotinib
SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pyrotinib：Tablet, 160mg / tablet, 80mg / tablet, oral
Experimental: SHR-A1811Combined Pertuzumab
Drug: SHR-A1811；Pertuzumab
SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Pertuzumab：Injection, 420 Mg (14 ml) / bottle, intravenous drip
Experimental: SHR-A1811Combined Albumin-bound Paclitaxel
Drug: SHR-A1811；Albumin paclitaxel
SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Albumin paclitaxel：Injection, 100mg / box, intravenous drip
Experimental: SHR-A1811Combined Adebrelimab
Drug: SHR-A1811；Adebrelimab
SHR-A1811：Lyophilized powder injection, 100mg / bottle, intravenous drip Adebrelimab：Injection, 12ml: 0.6g/bottle, intravenous drip

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
DLT（Phase I (dose exploration phase) ）
Time Frame: 21 days after the first administration of each subject
21 days after the first administration of each subject
AE（Phase I (dose exploration phase) ）
Time Frame: from Day1 to 40 or 90 days after last dose
from Day1 to 40 or 90 days after last dose
Incidence and severity of serious adverse events (SAE)（Phase I (dose exploration phase) ）
Time Frame: from Day1 to 40 or 90 days after last dose
from Day1 to 40 or 90 days after last dose
Objective response rate（Phase II (efficacy expansion phase)）
Time Frame: Two years after the last subject was enrolled in the group
Two years after the last subject was enrolled in the group

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
PK parameter: Cmin of SHR-A1811（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: Cmax of SHR-A1811（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: AUC0-t of SHR-A1811（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: Cmin of Pyrotinib（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: C4h of Pyrotinib（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Immunogenicity of SHR-A1811（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Objective Response Rate（Phase I secondary endpoint）
Time Frame: from first dose to disease progression or death, whichever comes first, up to 3 years
from first dose to disease progression or death, whichever comes first, up to 3 years
Duration of response（Phase I secondary endpoint）
Time Frame: from first dose to disease progression or death, whichever comes first, up to 3 years
from first dose to disease progression or death, whichever comes first, up to 3 years
Progression Free Survival（Phase I secondary endpoint）
Time Frame: from first dose to disease progression or death, whichever comes first, up to 3 years
from first dose to disease progression or death, whichever comes first, up to 3 years
AE（Phase II secondary study endpoint）
Time Frame: from Day1 to 40 or 90 days after last dose
from Day1 to 40 or 90 days after last dose
Incidence and severity of serious adverse events (SAE)（Phase II secondary study endpoint）
Time Frame: from Day1 to 40 or 90 days after last dose
from Day1 to 40 or 90 days after last dose
PK parameter: Cmin, Cmax, and AUC0-t of SHR-A1811（Phase II secondary study endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: Cmin, C4h of Pyrotinib:（Phase II secondary study endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Immunogenicity of SHR-A1811（Phase II secondary study endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Duration of response（Phase II secondary study endpoint）
Time Frame: from first dose to disease progression or death, whichever comes first, up to 3 years
from first dose to disease progression or death, whichever comes first, up to 3 years
Progression Free Survival（Phase II secondary study endpoint）
Time Frame: from first dose to disease progression, or death, whichever comes first, up to 3 years
from first dose to disease progression, or death, whichever comes first, up to 3 years
Event-Free Survival Rate（Phase II secondary study endpoint）
Time Frame: from first dose to disease progression, disease recurrence, or death, whichever comes first, up to 3 years
from first dose to disease progression, disease recurrence, or death, whichever comes first, up to 3 years
PK parameter: Cmin of Adebrelimab（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Immunogenicity of Adebrelimab（Phase I secondary endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
PK parameter: Cmin of Adebrelimab（Phase II secondary study endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years
Immunogenicity of Adebrelimab（Phase II secondary study endpoint）
Time Frame: through study completion, an average of 2 years
through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Jiangsu HengRui Medicine Co., Ltd.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
May 23, 2022

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2025

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2025

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
April 19, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
April 25, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 29, 2022

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
September 15, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
September 14, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
September 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • SHR-A1811-II-202

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings